JPWO2020243442A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020243442A5 JPWO2020243442A5 JP2021570824A JP2021570824A JPWO2020243442A5 JP WO2020243442 A5 JPWO2020243442 A5 JP WO2020243442A5 JP 2021570824 A JP2021570824 A JP 2021570824A JP 2021570824 A JP2021570824 A JP 2021570824A JP WO2020243442 A5 JPWO2020243442 A5 JP WO2020243442A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- fgfr3
- infigratinib
- acceptable salt
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 64
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 claims 41
- 229950005712 infigratinib Drugs 0.000 claims 41
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 39
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 39
- 150000003839 salts Chemical class 0.000 claims 39
- 206010044412 transitional cell carcinoma Diseases 0.000 claims 29
- 208000023747 urothelial carcinoma Diseases 0.000 claims 23
- 230000035772 mutation Effects 0.000 claims 11
- 108700028369 Alleles Proteins 0.000 claims 10
- 239000000090 biomarker Substances 0.000 claims 10
- 230000014509 gene expression Effects 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 230000004927 fusion Effects 0.000 claims 8
- 206010005003 Bladder cancer Diseases 0.000 claims 6
- 238000005259 measurement Methods 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 5
- 229960004316 cisplatin Drugs 0.000 claims 5
- 238000013270 controlled release Methods 0.000 claims 5
- 230000008707 rearrangement Effects 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000003205 muscle Anatomy 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 238000011200 topical administration Methods 0.000 claims 4
- 101150025764 FGFR3 gene Proteins 0.000 claims 3
- 102200143269 rs121913482 Human genes 0.000 claims 3
- 102200143266 rs121913483 Human genes 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 239000002955 immunomodulating agent Substances 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 238000009099 neoadjuvant therapy Methods 0.000 claims 2
- 101000836150 Homo sapiens Transforming acidic coiled-coil-containing protein 3 Proteins 0.000 claims 1
- 102100027048 Transforming acidic coiled-coil-containing protein 3 Human genes 0.000 claims 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 claims 1
- 238000009799 cystectomy Methods 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 210000000244 kidney pelvis Anatomy 0.000 claims 1
- 238000011227 neoadjuvant chemotherapy Methods 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 229920001296 polysiloxane Polymers 0.000 claims 1
- 102200143295 rs78311289 Human genes 0.000 claims 1
- 210000000626 ureter Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962855277P | 2019-05-31 | 2019-05-31 | |
| US62/855,277 | 2019-05-31 | ||
| US201962906194P | 2019-09-26 | 2019-09-26 | |
| US62/906,194 | 2019-09-26 | ||
| PCT/US2020/035140 WO2020243442A1 (en) | 2019-05-31 | 2020-05-29 | Methods of treating urinary system cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022534118A JP2022534118A (ja) | 2022-07-27 |
| JPWO2020243442A5 true JPWO2020243442A5 (enExample) | 2023-05-19 |
Family
ID=73553913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021570824A Pending JP2022534118A (ja) | 2019-05-31 | 2020-05-29 | 泌尿器系がんを治療する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220233537A1 (enExample) |
| EP (1) | EP3976833A4 (enExample) |
| JP (1) | JP2022534118A (enExample) |
| KR (1) | KR20220088830A (enExample) |
| CN (1) | CN114207151A (enExample) |
| AU (1) | AU2020282816A1 (enExample) |
| CA (1) | CA3141871A1 (enExample) |
| IL (1) | IL288408A (enExample) |
| MX (1) | MX2021014524A (enExample) |
| PH (1) | PH12021552973A1 (enExample) |
| SG (1) | SG11202112932QA (enExample) |
| WO (1) | WO2020243442A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022133212A1 (en) * | 2020-12-18 | 2022-06-23 | Qed Therapeutics, Inc. | Methods of treating achondroplasia |
| CN117982507A (zh) * | 2022-11-01 | 2024-05-07 | Qed医药股份有限公司 | 英菲格拉替尼在治疗胃癌和腺癌中的用途 |
| CN115785001B (zh) * | 2022-11-23 | 2023-09-15 | 斯坦德药典标准物质研发(湖北)有限公司 | 一种英菲格拉替尼的制备方法 |
| CN117558346B (zh) * | 2023-09-01 | 2024-12-03 | 上海仁东医学检验所有限公司 | Utuc分子分型及预后预测模型构建方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1960547A2 (en) * | 2005-12-08 | 2008-08-27 | Novartis AG | Effects of inhibitors of fgfr3 on gene transcription |
| EP3939614A1 (en) * | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
| TWI541022B (zh) * | 2013-12-18 | 2016-07-11 | 應克隆公司 | 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法 |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| SMT202200177T1 (it) * | 2014-09-26 | 2022-05-12 | Janssen Pharmaceutica Nv | Uso di gruppi di geni mutanti del fgfr nell'identificazione di pazienti affetti da cancro che saranno responsivi al trattamento con un inibitore del fgfr |
| US20180222983A1 (en) * | 2017-02-06 | 2018-08-09 | Bioclin Therapeutics, Inc. | Methods, compositions, and kits for treatment of cancer |
| IL319255A (en) * | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| EA201991818A1 (ru) * | 2017-12-20 | 2020-02-05 | Янссен Фармацевтика Нв | Лечение рака |
-
2020
- 2020-05-29 CN CN202080053765.5A patent/CN114207151A/zh active Pending
- 2020-05-29 US US17/613,652 patent/US20220233537A1/en active Pending
- 2020-05-29 SG SG11202112932QA patent/SG11202112932QA/en unknown
- 2020-05-29 JP JP2021570824A patent/JP2022534118A/ja active Pending
- 2020-05-29 KR KR1020217043300A patent/KR20220088830A/ko active Pending
- 2020-05-29 AU AU2020282816A patent/AU2020282816A1/en not_active Abandoned
- 2020-05-29 PH PH1/2021/552973A patent/PH12021552973A1/en unknown
- 2020-05-29 CA CA3141871A patent/CA3141871A1/en active Pending
- 2020-05-29 EP EP20815357.7A patent/EP3976833A4/en active Pending
- 2020-05-29 MX MX2021014524A patent/MX2021014524A/es unknown
- 2020-05-29 WO PCT/US2020/035140 patent/WO2020243442A1/en not_active Ceased
-
2021
- 2021-11-25 IL IL288408A patent/IL288408A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20190052062A (ko) | Raf 억제제 및 erk 억제제를 포함하는 치료적 조합 | |
| US20180360846A1 (en) | Cenicriviroc combination therapy for the treatment of fibrosis | |
| AU2015230986A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| JP7651620B2 (ja) | 経口リファマイシンｓｖ組成物 | |
| KR20240056564A (ko) | T 세포 림프종을 치료하기 위한 약물을 제조하는 데 있어서 ezh2 억제제의 용도 | |
| JP2015514062A5 (enExample) | ||
| JP5757544B2 (ja) | 癌治療に用いられるベムラフェニブとインターフェロンを含む併用療法 | |
| TW201919618A (zh) | 用於治療肉瘤的化合物 | |
| WO2018171405A1 (zh) | 一种选择性tnfr1拮抗肽sn10及其在炎症性肠病中的应用 | |
| US20190343806A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| JPWO2020243442A5 (enExample) | ||
| JP2020519576A (ja) | 肝細胞癌の治療 | |
| CN117919234A (zh) | 一种萘酰胺化合物治疗耐药性肿瘤的用途 | |
| WO2020236667A1 (en) | Methods of treating cancer | |
| BR112021008688A2 (pt) | tratamento para arterite de célula gigante | |
| Leung et al. | Case report: failure of subcutaneous ivermectin in treating Strongyloides hyperinfection | |
| CN113840608A (zh) | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| CN113134080A (zh) | 抗pd-1抗体和呋喹替尼联合在制备治疗癌症的药物中的用途 | |
| EP4475841A1 (en) | Methods of weight loss and preserving skeletal muscle mass | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| Ketch et al. | Treatment monitoring utilizing ctDNA-based molecular residual disease detection in early-stage endometrial cancer | |
| CN109963847A (zh) | 治疗实体瘤的方法 | |
| CN101879151A (zh) | 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用 | |
| WO2022161364A1 (zh) | 通路调节剂、含其的药物组合物、其用途和采用其的治疗方法 | |
| CN106061505A (zh) | 用于治疗癌症的含pi3k抑制剂的药物组合 |